Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 21, Issue SUPPL. 5, 2010, Pages

  Pavlidis, N ^a   Briasoulis, E ^a   Pentheroudakis, G ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE PLACENTA ISOENZYME; ALPHA FETOPROTEIN; CALCITONIN; CAPECITABINE; CARBOPLATIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CHROMOGRANIN A; CISPLATIN; CYTOKERATIN 20; CYTOKERATIN 7; DESMIN; DOCETAXEL; ESTROGEN RECEPTOR; ETOPOSIDE; FLUORODEOXYGLUCOSE; GEMCITABINE; IRINOTECAN; NEURON SPECIFIC ENOLASE; OXALIPLATIN; PACLITAXEL; PROGESTERONE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN S 100; SYNAPTOPHYSIN; THYROGLOBULIN; VIMENTIN;

ADENOCARCINOMA; ANAMNESIS; ARTICLE; BLOOD ANALYSIS; CANCER OF UNKNOWN PRIMARY SITE; CANCER RADIOTHERAPY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC PROCEDURE; ENDOSCOPY; EUROPE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAMMOGRAPHY; MEDICAL SOCIETY; NEUROENDOCRINE TUMOR; OCCULT BLOOD; OUTCOME ASSESSMENT; PATIENT CARE; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA; URINALYSIS;

DRUG THERAPY; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KERATIN-20; KERATIN-7; LYMPHATIC METASTASIS; MALE; META-ANALYSIS AS TOPIC; NEOPLASM STAGING; NEOPLASMS, UNKNOWN PRIMARY; PROSTATE-SPECIFIC ANTIGEN; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77954323101     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq193     Document Type: Article

References (18)

1. Briasoulis E, Pavlidis N. Cancer of unknown primary origin. Oncologist 1997; 2: 142-152.
2. Pavlidis N, Briasoulis E, Hainsworth J et al. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003; 39: 1990-2005.
3. Pentheroudakis G, Briasoulis E, Pavlidis N. Cancer of unknown primary site: missing primary or missing biology? Oncologist 2007; 12: 418-425.
4. Klein CA. Parallel progression of primary tumours and metastases. Nat Rev Cancer 2009; 9: 302-312.
5. Podsypanina K, Du YC, Jechlinger M et al. Seeding and propagation of untransformed mouse mammary cells in the lung. Science 2008; 321: 1841-1844.
6. Oien KA. Pathologic evaluation of unknown primary cancer. Semin Oncol 2009; 36: 8-37.
7. Abbruzzese JL, Abbruzzese MC, Lenzi R et al. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 1995; 13: 2094-2103.
8. Pentheroudakis G, Golfinopoulos V, Pavlidis N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer 2007; 43: 2026-2036.
9. Pentheroudakis G, Greco FA, Pavlidis N. Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review. Cancer Treat Rev 2009; 35: 221-227.
10. Culine S, Kramar A, Saghatchian M et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 2002; 20: 4679-4683.
11. Bugat R, Bataillard A, Lesimple T et al. Summary of the standards, options and recommendations for the management of patients with carcinoma of unknown primary site (2002). Br J Cancer 2003; 89 (Suppl 1): S59-S66.
12. Seve P, Billotey C, Broussolle C et al. The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer 2007; 109: 292-299.
13. Pavlidis N. Forty years experience of treating cancer of unknown primary. Acta Oncol 2007; 46: 592-601.
14. Spigel DR, Hainsworth JD, Greco FA. Neuroendocrine carcinoma of unknown primary site. Semin Oncol 2009; 36: 52-59.
15. Pentheroudakis G, Pavlidis N. Serous papillary peritoneal carcinoma: unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review. Crit Rev Oncol Hematol 2009 Nov 6 Epub PMID 19897387.
16. Pentheroudakis G, Lazaridis G, Pavlidis N. Axillary nodal metastases from carcinoma of unknown primary (CUPAx): a systematic review of published evidence. Breast Cancer Res Treat 2010; 119: 1-11.
17. Pavlidis N, Pentheroudakis G, Plataniotis G. Cervical lymph node metastases of squamous cell carcinoma from an unknown primary site: a favourable prognosis subset of patients with CUP. Clin Transl Oncol 2009; 11: 340-348.
18. Golfinopoulos V, Pentheroudakis G, Salanti G et al. Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis. Cancer Treat Rev 2009; 35: 570-573.